Drug Approval | December 12, 2023
Merck Animal Health receives positive CVMP opinion for an injectable formulation of Bravecto
The CVMP recommends the product for approval for the treatment and persistent killing of fleas
The CVMP recommends the product for approval for the treatment and persistent killing of fleas
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Cresemba is the only azole antifungal therapy approved for pediatric patients as young as one affected by these serious, potentially life-threatening infections
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Express Scripts to add Zepbound to National Preferred Formulary
NATCO temporarily shut down the operations due to cyclone with flooding/water logging of the factory premises
Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
Subscribe To Our Newsletter & Stay Updated
